Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2016
This is a phase II randomized clinical trial to study the effect of COX-2 inhibitor Celecoxib and EGFR tyrosine kinase inhibitor Erlotinib alone or in combination on molecular markers of apoptosis and angiogenesis.
Epistemonikos ID: a3ce53d34c0d7bf0d169f685920a731e7c52687d
First added on: May 12, 2024